Clinical Application of Dual Sentinel Lymph Node Staining Method in Breast Cancer Patients
Breast Cancer
About this trial
This is an interventional other trial for Breast Cancer focused on measuring Neoadjuvant chemotherapy, Indocyanine green (ICG), Radioisotope (RI), Near infrared fluorescence camera
Eligibility Criteria
Inclusion Criteria:
- breast cancer patients who receive neoadjuvant therapy (chemotherapy,hormonal therapy, targeted therapy)
- cN1-cN2 or cN3( but must be complete response status)on tumor lymphnode metastasis classification( TNM) after neoadjuvant therapy.
- ECOG Performance status 0 or 1
- consented patients with more than 20 years, less than 70 years
Exclusion Criteria:
- history of breast cancer
- early stage breast cancer
- history of excisional or incisional biopsy or axillary dissection
- inflammatory breast carcinoma
- cN3 on tumor lymphnode metastasis classification(TNM)
- stage 4 breast cancer
- pregnancy
Sites / Locations
- National Cancer Center
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Radioisotope (RI)
Indocyanine green (ICG) +RI
Using RI only as SLNB mapping in breast cancer patients who receive neoadjuvant chemotherapy. Interventions - patient assigend RI groups are injected only RI fill the Primay Case Report Form during surgery PCRF including SLN detection time, duration of SLN approch time to 1st sentinel node dection time, incision length , depth, RI +/- .
Dual sentinel node staining method using mixture of indocyanine green (ICG) and radioisotope (RI) in breast cancer patients who receive neoadjuvant chemotherapy. Interventions - patient assigend RI groups are injected RI +ICG prepare fluorescence camera when the surgery begin surgeon uses the camera to decect fluorescence flow on SLN fill the Primay Case Report Form during surgery PCRF including SLN detection time, duration of SLN approch time to 1st sentinel node dection time, incision length , depth, RI +/- , ICG+/-